Merck & Co., Inc. MRK NYSE

Merck & Co., Inc. (MRK) reported total assets of $136.87B and total liabilities of $84.2B for fiscal year 2025, resulting in total equity of $52.66B.

The company held $14.57B in cash and short-term investments. Total debt stood at $50.53B, with net debt of $35.97B. The Debt-to-Equity (D/E) ratio was 0.96 (moderate).

Current ratio is 1.54, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (83/100, Pass) — Debt-to-Equity of 0.96, current ratio of 1.54 — balance sheet is strong
• MOAT (94/100) — Total assets $136.87B and equity $52.66B support the company's competitive scale
• VALUE (84/100) — Debt-to-Equity 0.96 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 83/100 with 7/7 criteria passed.

LLY

Eli Lilly and Company

$922.50

-0.76%

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%

AZN

AstraZeneca PLC

$204.38

+1.06%

NVS

Novartis AG

$153.38

-0.71%

TMO

Thermo Fisher Scientific Inc.

$527.22

+2.53%

AMGN

Amgen Inc.

$350.95

+0.32%

ABT

Abbott Laboratories

$101.07

+0.38%